News

Carl D. Regillo, MD, FACS, FASRS, discussed recent data from the DAVIO 2 trial in his presentation at the virtual Angiogenesis, Exudation, and Degeneration 2024.

Dr. Carl Regillo provided an overview of topline results and a deep dive into subgroup analyses of DAVIO 2 trial data.

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.

Early-onset drusen maculopathy (EODM), is part of the age-related macular degeneration (AMD) phenotype that occurs in individuals under 55 years of age.

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants.

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants

SriniVas R. Sadda, MD, sat down with David Hutton of Ophthalmology Times to discuss his presentation about precursor lesions for development of atrophy and AMD from the Angiogenesis Exudation and Degeneration 2024 event.

Researchers aimed to develop a translational map to understand how advanced imaging biomarkers manifest in typical diagnostic imaging

Trial will analyze efficacy, safety of AVD-104 versus avacincaptad pegol to treat GA

Kiora Pharmaceuticals and Théa Open Innovation will develop and commercialise KIO-301 for the treatment of inherited retinal diseases

Under the terms of the agreement, Kiora Pharmaceuticals and Théa Open Innovation will develop and commercialize KIO-301 for the treatment of inherited retinal diseases in a deal valued at up to $301 million.

A new study out of Guangzhou, China found that individuals younger than 18 years of age and experiencing high myopia are at a high risk of progressively worsening myopic maculopathy.

The agreement settles Zeiss’s lawsuit against Topcon’s U.S.-based subsidiaries that had been set to start this month in U.S. federal court for the Northern District of California.

In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.

According to the company, the deals from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024.

This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed. One company is taking exception with the study.

Many options with one single Nd:YAG laser

Wilmer's expansive focus and deep bench are advancing the understanding of artificial intelligence tools and potential ophthalmic applications.

Enhanced detection and diagnosis of common and severe diseases

According to the company, Eyconis Inc. is developed with a $150 million commitment from external investors.

The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

An in-depth case study conversation

Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.